<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2014.00554</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Perspective Article</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Myeloid Colony-Stimulating Factors as Regulators of Macrophage Polarization</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hamilton</surname> <given-names>Thomas A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/152692"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname> <given-names>Chenyang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pavicic</surname> <given-names>Paul G.</given-names> <suffix>Jr.</suffix></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Datta</surname> <given-names>Shyamasree</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation</institution>, <addr-line>Cleveland, OH</addr-line>, <country>USA</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Charles Dudley Mills, BioMedical Consultants, USA</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Robert Adam Harris, Karolinska Institutet, Sweden; Cordula M. Stover, University of Leicester, UK</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Thomas A. Hamilton, Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA e-mail: <email>hamiltt&#x00040;ccf.org</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology.</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>21</day>
<month>11</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="collection">
<year>2014</year>
</pub-date>
<volume>5</volume>
<elocation-id>554</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>08</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>10</month>
<year>2014</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2014 Hamilton, Zhao, Pavicic and Datta.</copyright-statement>
<copyright-year>2014</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>The scope of functional heterogeneity in macrophages has been defined by two polarized end states known as M1 and M2, which exhibit the proinflammatory activities necessary for host defense and the tissue repair activities required for restoration of homeostasis, respectively. Macrophage populations in different tissue locations exist in distinct phenotypic states across this M1/M2 spectrum and the development and abundance of individual subsets result from the local and systemic action of myeloid colony-stimulating factors (CSFs) including M-CSF and GM-CSF. These factors have relatively non-overlapping roles in the differentiation and maintenance of specific macrophage subsets. Furthermore, there is now evidence that CSFs may also regulate macrophage phenotype during challenge. Cell culture studies from multiple laboratories demonstrate that macrophages developed in the presence of GM-CSF exhibit amplified response to M1 polarizing stimuli while M-CSF potentiates responses to M2 stimuli. As a consequence, these factors can be important determinants of the magnitude and duration of both acute and chronic inflammatory pathology and may, therefore, be potential targets for therapeutic manipulation in specific human disease settings.</p>
</abstract>
<kwd-group>
<kwd>macrophage activation</kwd>
<kwd>macrophage colony-stimulating factor</kwd>
<kwd>granulocyte macrophage colony-stimulating factor</kwd>
<kwd>inflammation</kwd>
<kwd>cytokines</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="63"/>
<page-count count="6"/>
<word-count count="5180"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>The Macrophage Polarization Paradigm: Classical (M1) and Alternative (M2) Activation Phenotypes</title>
<p>The mononuclear phagocyte system is known to exhibit substantial functional heterogeneity (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>). Though the scope of such heterogeneity is dramatically large, the prevailing concept of heterogeneity is organized around two polarized endpoints known as classical and alternative activation, also often termed M1 and M2, respectively (<xref ref-type="bibr" rid="B4">4</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>). These polarized states represent the capacities to initiate inflammatory response, carry out anti-microbial function, and promote Th1/Th17 adaptive immune responses for M1, or, for M2, to phagocytize debris, promote wound healing, antagonize destructive inflammation, and suppress adaptive immunity. These functional activities are mediated by molecular features that include, for M1, the production of proinflammatory cytokines, co-stimulatory molecules including CD80/86, effector enzymes such as iNOS, and NADPH oxidase or, for M2, anti-inflammatory cytokines, immunosuppressive arginase, and scavenger receptors (CD163) (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Importantly, there are multiple subsets of macrophages with relatively non-overlapping functional responsibilities and this additional heterogeneity must be superimposed upon the M1/M2 paradigm (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>). Resident macrophage populations exhibit many common features but are not identical, often deriving from distinct origins and showing a broad spectrum of functional potential (<xref ref-type="bibr" rid="B10">10</xref>). It is noteworthy that most resident tissue macrophages are capable of self-replenishment and generally do not derive from circulating monocytes (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B11">11</xref>). There are two major categories of monocytes found in the circulation. In the mouse, these are characterized as Ly6C-hi/CCR2<sup>hi</sup> and Ly6C<sup>lo</sup>/CX3CR1<sup>hi</sup>. The former is likely the source of most infiltrating inflammatory macrophages or dendritic cells, while the latter is a patrolling and longer lived cell population that provides maintenance of the vascular endothelium (<xref ref-type="bibr" rid="B7">7</xref>). The understanding of macrophage subsets and their developmental origin has advanced dramatically through the application of fate mapping and other transgenic strategies (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B11">11</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>). Moreover, the molecular features responsible for distinct functional activities (anti-microbial, inflammatory, reparative, etc.) have been defined through detailed analysis of isolated cell populations and cell type-specific transgenic manipulation (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B14">14</xref>). These macrophage subpopulations exhibit many molecular similarities that reflect their common myeloid origin but each has very distinct responsibilities and their inter-conversion appears to be limited under steady-state conditions (<xref ref-type="bibr" rid="B9">9</xref>). Moreover, each of these subset populations can be induced to exhibit M1 or M2 like functional polarization.</p>
<p>The concepts of classical and alternative activation or even M1 and M2 markedly oversimplify the spectrum of macrophage phenotypes that exist within vertebrate organisms (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B15">15</xref>). The number of individual phenotypes will, in part, depend upon the number of gene products that are measured and the degree to which gene expression events are independent (<xref ref-type="bibr" rid="B16">16</xref>). Furthermore, the spectrum of environmental cues encountered by macrophages is highly complex both in number and exposure sequence. Hence, the combinatorial spectrum of possible phenotypes is extremely large. As a simplifying principle, the number of specific molecular endpoints used to define phenotype can be limited to those activities and molecules requisite to the functions of interest (e.g., anti-microbial, reparative, etc.). This will enable comparison of macrophage populations within different physiologic and pathologic circumstances and evaluation of how the specific molecular characteristics may vary with cell subset and stimulus environment.</p>
<p>Finally, it is also important to recognize that inflammation is a dynamic process that is well recognized to proceed in stages with an early proinflammatory function followed by a transition to healing and restoration of tissue homeostasis (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). While this process includes the temporally distinct recruitment of multiple cell populations that can provide different aspects of the evolving functional features, there is also reason to believe that infiltrating inflammatory monocytes may cycle through different states of functional activity that are, at a minimum, reminiscent of the M1 and M2 categories (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>).</p>
</sec>
<sec id="S2">
<title>Regulation of Polarization</title>
<p>Classically and alternatively activated (M1 or M2) macrophage phenotypes are defined by the specific molecular characteristics induced in response to prototypic pro- and anti-inflammatory stimuli [e.g., IFN&#x003B3;, Toll-like receptor (TLR) agonists, IL-4/IL-13, IL-10, etc.] (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Such molecular correlates are now used with increasing frequency to identify populations of M1 or M2 like macrophages in different physiologic settings. Thus, M1 macrophages express high levels of IL-12 or IL-23, TNF&#x003B1;, IL-1&#x003B1;/&#x003B2;, chemokines eliciting neutrophil, inflammatory monocyte, and proinflammatory T lymphocyte infiltration (CXCL1-3, 8, CCL2, CXCL9, and CXCL10), CD80/86, CD64, MARCO, iNOS, and reactive oxygen species (hydroxyl radicals and H<sub>2</sub>O<sub>2</sub>) induced by M1 polarizing stimuli. Correlates of the M2 phenotype include IL-10, TGF&#x003B2;, arginase, YM1, FIZZ1 (in the mouse), the mannose receptor (CD206), and scavenger receptors, such as CD163 induced following exposure to IL-4, IL-13, TGF&#x003B2;, IL-10, and other agents.</p>
<p>In this context, M1 and M2 phenotypes are often presented as relating to the actions of Th1 and Th2 cell subsets, respectively, because of the Th1 and Th2 lymphokine-based modulation of their defining features (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B21">21</xref>). It is evident, however, that polarized macrophage function existed prior to the development of adaptive immunity in evolution (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). Moreover, mice with T- and B-cell deficiency still possess the potential for polarized function demonstrating that the M1 and M2 concept can exist in the absence of adaptive immunity and its products (<xref ref-type="bibr" rid="B4">4</xref>). Nevertheless, the normal vertebrate immune system operates with a full spectrum of immune cell populations and their products clearly influence the macrophage polarization process. Indeed, it is likely that macrophages will encounter both M1 and M2 polarizing stimuli simultaneously within the inflamed tissue microenvironment. The complexity of response to this may reasonably explain the large spectrum of macrophage phenotypes encountered in cell populations <italic>in vivo</italic> and the variability in markers of polarization.</p>
<p>Macrophage populations may also exhibit a predisposition for polarization toward the M1 or M2 phenotype. For example, different strains of mice and rats have been shown to have skewed patterns of activation potential that ultimately correlate with their innate and adaptive immune functionality (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>). Furthermore, it is well recognized that macrophages in different anatomic or physiologic settings exhibit dramatically different capacities for polarization. Importantly, there are agents that, by themselves, do not induce expression of common polarization markers but which can alter response to stimulation with classical M1 or M2 stimuli. Because most, if not all macrophage populations, can respond to either M1 or M2 stimuli, the tone of a response may be set by differential regulation of sensitivity to polarizing stimuli. Hence, agents that promote priming of macrophages for enhanced or diminished response to classical or alternative activation are likely to be important determinants of the character and temporal patterns of macrophage functional change in the course of response to injury and infection.</p>
<p>The myeloid colony-stimulating factors (CSFs) M-CSF and GM-CSF are known to modulate macrophage phenotype (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). While both agents were first identified as inducers of myeloid cell differentiation and proliferation in cultured bone marrow progenitors, many studies illustrate their importance in the magnitude, duration, and character of many forms of inflammatory response (<xref ref-type="bibr" rid="B26">26</xref>&#x02013;<xref ref-type="bibr" rid="B30">30</xref>). Though GM-CSF is associated with classical or M1 activation while M-CSF is linked with alternative or M2 activation, neither factor is a potent stimulus of definitive polarization markers, when compared with prototypic polarizing stimuli (e.g., IFN&#x003B3;, TLRs, IL-4, IL-10, etc.) (<xref ref-type="bibr" rid="B31">31</xref>&#x02013;<xref ref-type="bibr" rid="B33">33</xref>). Instead, GM-CSF and M-CSF appear to induce a state in which macrophages are primed for M1 and M2 endpoints, respectively.</p>
</sec>
<sec id="S3">
<title>Molecular and Cellular Phenotypes Produced by M-CSF and GM-CSF <italic>In vitro</italic></title>
<p>While receptor signaling mechanisms mediating responses to M-CSF and GM-CSF are appreciated in basic detail (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B26">26</xref>), understanding of how these agents modulate functional polarization remains obscure. The potential for CSFs to regulate the responses of mature myeloid cell populations is well recognized. For example, the capacity of GM-CSF, but not M-CSF, to generate DCs in culture clearly demonstrated distinct functional roles (<xref ref-type="bibr" rid="B34">34</xref>). Verreck et al. initially demonstrated that GM-CSF or M-CSF treatment of myeloid cells in culture was able to selectively alter the magnitude of M1 or M2 polarized phenotypes following appropriate stimulation (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>). While GM-CSF cultured macrophages stimulated with LPS&#x02009;&#x000B1;&#x02009;IFN&#x003B3; produced large amounts of IL-23 or IL-12 and little IL-10, M-CSF cultured macrophages were unable to generate either IL-12 or IL-23 but did produce significant amounts of IL-10 under the same conditions. GM-CSF-treated cells produced appreciably higher levels of other proinflammatory cytokines including TNF, IL-18, IL-1&#x003B2;, and IL-6 in comparison to those grown in M-CSF. Furthermore, M-CSF-treated cells were more phagocytic but less competent in antigen presentation when compared with GM-CSF treated cells. For the most part, the growth factor-treated cells did not exhibit the full M1 or M2 phenotypes in otherwise unstimulated state but rather showed polarized sensitivity for corresponding response to IFN&#x003B3;/TLR signaling. These findings led the authors to conclude that GM-CSF and M-CSF were promoting the development of monocyte-macrophages predisposed to exhibit differential M1 and M2 phenotypes, respectively. These findings were confirmed and extended by Fleetwood et al. using bone marrow derived macrophages from mice cultured in either GM-CSF or M-CSF (<xref ref-type="bibr" rid="B33">33</xref>). Interestingly, though GM-CSF is frequently used to generate DCs from bone marrow progenitors, the cells arising from such cultures more closely resemble macrophages than dendritic cells based upon whole genome profiling (<xref ref-type="bibr" rid="B35">35</xref>). Though there are many similarities between human being and mouse macrophages in different polarized states, there also appear to be many differences (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B35">35</xref>&#x02013;<xref ref-type="bibr" rid="B37">37</xref>). Despite these findings, there remain important questions about the strict relationship between these two factors and the molecular/functional phenotype definitions for M1 and M2. Thus, studies in both mouse and human cells show that the effects of GM-CSF and M-CSF on gene expression do not map exactly with M1 and M2 marker expression, even following stimulation (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>).</p>
<p>In the context of the hypothesis that macrophage predisposition is an important determinant of polarized phenotype expression, there are certainly other natural ligands that have the capacity to alter macrophage sensitivity to specific polarization stimuli (<xref ref-type="bibr" rid="B40">40</xref>&#x02013;<xref ref-type="bibr" rid="B45">45</xref>). Because inflammatory responses <italic>in vivo</italic> will always occur in a complex stimulus environment, these additional agents are likely to co-operate with or antagonize the actions of the CSFs. PPAR&#x003B3;, in particular, has been reported to be required for development of alternatively activated macrophages in the context of insulin resistance and metabolic inflammatory disease (<xref ref-type="bibr" rid="B46">46</xref>). The tyrosine kinase receptor CD136 (RON, MST1R) can also modulate sensitivity for M2-like activators, in part by altering the sensitivity to TLR stimulation (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B47">47</xref>). In contrast to these agents, NOTCH and its ligand RBP-J, are reported to promote M1-like responses via alterations in intracellular signaling factors including IRF8 and SOCS3 (<xref ref-type="bibr" rid="B40">40</xref>). Indeed, the sensitivity of myeloid cell populations to polarizing stimuli appears to be controlled in part by alterations in the abundance or activity of the signaling pathway components that mediate responses to pro- and anti-inflammatory stimuli (<xref ref-type="bibr" rid="B41">41</xref>&#x02013;<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>). Thus, signaling adaptors, protein kinases, protein phosphatases, and transcription factors including members of the IRF, SOCS, Tec, and KLF families have all been implicated in controlling either M1 or M2 polarization. The mechanisms through which stimulus sensitivity is altered by ligand/receptor pairs, such as the CSFs, as well as others mentioned above remains to be fully elucidated but intracellular signaling factors are likely to be important targets.</p>
</sec>
<sec id="S4">
<title>Role of M-CSF and GM-CSF in Macrophage Functional Polarization <italic>In vivo</italic></title>
<p>M-CSF and GM-CSF have distinct effects on the development and expansion of myeloid cell populations in different anatomic settings (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Based upon studies of mice with targeted deletion of ligand and/or receptor genes, M-CSF is known to be required for the production and maintenance of many (though not all) tissue macrophage populations (<xref ref-type="bibr" rid="B51">51</xref>). In this regard, distinctions between receptor and ligand deficient mice revealed the existence of a second ligand (IL-34), which is now known to be necessary for the maintenance of a subset of tissue macrophage populations (microglia and Langerhans cells) (<xref ref-type="bibr" rid="B52">52</xref>). M-CSF and IL-34 function in homeostatic maintenance of tissue-resident macrophage populations through promoting viability and proliferation and both drive predisposition to M2 character (<xref ref-type="bibr" rid="B53">53</xref>). While M-CSF is found in the serum of healthy individuals and can be produced constitutively by epithelia, fibroblasts, endothelial cells, and by macrophages themselves, its expression can be elevated by inflammatory conditions in many cells including macrophages as well as T and B lymphocytes (<xref ref-type="bibr" rid="B27">27</xref>). In contrast to M-CSF or IL-34, GM-CSF deficiency has little impact on steady-state tissue macrophage populations with the exception of those found in the lung (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>). While GM-CSF is believed to be important for the development of infiltrating inflammatory DCs, recent findings show that M-CSF but not GM-CSF sensitivity is requisite for these cell populations (<xref ref-type="bibr" rid="B13">13</xref>). Importantly, GM-CSF, unlike M-CSF, is not detectable in most tissues at rest but expression is frequently induced during inflammatory or immune stimulation in many tissues and cell types (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>While studies using animals with global or cell-type restricted deficiencies in M-CSF or GM-CSF ligand/receptor function do provide insight into their relative contributions to macrophage phenotypes during inflammatory responses <italic>in vivo</italic>, the interpretation of such experiments should be viewed with caution due to the impact of such deficiencies on development and/or abundance of specific myeloid subsets. These studies are effectively complemented by transiently manipulating M- or GM-CSF levels using specific ligand delivery or ligand/receptor antagonism. Results from multiple studies indicate that both M-CSF and GM-CSF can modulate the magnitude and character of inflammatory response in multiple tissue specific disease models (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B54">54</xref>&#x02013;<xref ref-type="bibr" rid="B56">56</xref>). These include autoimmune encephalomyelitis (MS), atherosclerosis, arthritis, nephritis, lung inflammation, and cancer. In most cases, however, the mechanisms through which these endpoints are achieved have not been elucidated. Certainly, both factors have the capacity to promote survival and/or expansion of macrophage populations both systemically and in specific tissue locations and the decreased number of macrophages observed with CSF antagonism would likely result in reduced intensity and/or duration of disease (<xref ref-type="bibr" rid="B26">26</xref>). Multiple approaches including delivery of M-CSF, antibody-mediated depletion of the ligand, antibody-induced antagonism of receptor, or the use of receptor tyrosine kinase inhibitors have provided evidence supporting both positive and inhibitory roles for M-CSF in inflammatory diseases (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Interestingly, several recent reports demonstrate that antagonistic targeting of M-CSF can have appreciable benefit in tumor therapy as a consequence of altering the tumor-associated macrophage phenotype from M2 to M1 (<xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B57">57</xref>&#x02013;<xref ref-type="bibr" rid="B59">59</xref>).</p>
<p>There are several important considerations that can provide some speculative insight into the role for these CSFs in regulating the nature of macrophage polarization <italic>in vivo</italic>. First are the patterns of CSF expression within tissues both at rest and during inflammatory responses. While the expression of both factors can be amplified during response to various forms of tissue injury, it is apparent that M-CSF is produced constitutively in many tissues and is critical for the maintenance of resident tissue populations throughout the body. GM-CSF, in contrast, is rarely detectable except at times of injury and does not appear to be a critical determinant of macrophage numbers with a few exceptions (i.e., the lung). Second, resident macrophage populations are generally found to exhibit an M2-like phenotype under resting conditions, consistent with the need to minimize tissue damaging inflammatory reaction (<xref ref-type="bibr" rid="B10">10</xref>). This is certainly consistent with the ability of M-CSF to predispose toward an M2 phenotype in cell culture experiments involving both human monocytes and mouse bone marrow-derived macrophages. Third, GM-CSF has been shown to be a critical determinant of inflammatory injury in several model systems (<xref ref-type="bibr" rid="B60">60</xref>&#x02013;<xref ref-type="bibr" rid="B62">62</xref>). Particularly, T-cell derived GM-CSF was recently shown to be critical for disease phenotype in experimental autoimmune encephalomyelitis, generated by IL-23 action on Th17 cells (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). In this instance, GM-CSF selectively targeted infiltrating macrophages within the CNS. Finally, several studies examining responses to M-CSF and GM-CSF <italic>in vitro</italic> show that the M1/M2 phenotype can be reversibly modulated by GM-CSF/M-CSF exposure in cell culture and GM-CSF predisposition may be dominant (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B63">63</xref>) (Hamilton, unpublished). This is also supported by increased bioavailability (half-life) of GM-CSF, which might also contribute to its dominance relative to M-CSF. We would suggest then that M-CSF provides the default condition and will promote an M2 (healing) phenotype both at rest and in the absence of other forms of stimulation. Induced expression of GM-CSF (e.g., during adaptive T-cell driven immune responses) will provide the mechanism for retaining or re-expressing an M1 phenotype when conditions require (e.g., continued infection or injury). It is clear, however, that the specific effects of M-CSF and GM-CSF on macrophage polarization in cell culture models are unlikely to fully predict their effects <italic>in vivo</italic>. This reflects complexities associated with the variable nature of inflammatory injury, stimulus exposure, and distinct features of specific tissue microenvironments.</p>
</sec>
<sec id="S5">
<title>Unanswered Questions</title>
<p>Macrophage heterogeneity or phenotype polarization is an area of high current interest and the impact of myeloid CSFs on this process <italic>in vivo</italic> is evident but poorly understood. Hence, we pose the following outstanding questions regarding the roles that M-CSF and GM-CSF may play, particularly through modulating sensitivity to M1 and M2 promoting stimuli with the expectation that answers will help to clarify the process and provide insights to therapeutic application. (1) What mechanisms are involved in skewing responses to polarizing stimuli? Can we identify specific CSF-induced patterns of gene expression that are requisite to generating macrophages predisposed for more potent responses to cytokines and pattern recognition receptors? Can we correlate outcomes obtained <italic>in vitro</italic> with those obtained <italic>in vivo</italic>? (2) What are the sources and timing of M-CSF and GM-CSF expression within specific tissues during different forms of inflammatory response? Which myeloid cell populations are the targets of the CSFs and how is this co-ordinated with the need to enhance or diminish specific aspects of function over the full course of inflammatory response? (3) Finally, we must begin to consider not only the mechanisms through which M-CSF and GM-CSF operate but also how these stimuli are integrated with the host of other agents encountered within inflammatory settings that also have marked influence on M1/M2 skewing?</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>PJ</given-names></name> <name><surname>Wynn</surname> <given-names>TA</given-names></name></person-group>. <article-title>Protective and pathogenic functions of macrophage subsets</article-title>. <source>Nat Rev Immunol</source> (<year>2011</year>) <volume>11</volume>(<issue>11</issue>):<fpage>723</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1038/nri3073</pub-id><pub-id pub-id-type="pmid">21997792</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname> <given-names>TA</given-names></name> <name><surname>Chawla</surname> <given-names>A</given-names></name> <name><surname>Pollard</surname> <given-names>JW</given-names></name></person-group>. <article-title>Macrophage biology in development, homeostasis and disease</article-title>. <source>Nature</source> (<year>2013</year>) <volume>496</volume>(<issue>7446</issue>):<fpage>445</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.1038/nature12034</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname> <given-names>S</given-names></name> <name><surname>Taylor</surname> <given-names>PR</given-names></name></person-group>. <article-title>Monocyte and macrophage heterogeneity</article-title>. <source>Nat Rev Immunol</source> (<year>2005</year>) <volume>5</volume>(<issue>12</issue>):<fpage>953</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1038/nri1733</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname> <given-names>CD</given-names></name> <name><surname>Kincaid</surname> <given-names>K</given-names></name> <name><surname>Alt</surname> <given-names>JM</given-names></name> <name><surname>Heilman</surname> <given-names>MJ</given-names></name> <name><surname>Hill</surname> <given-names>AM</given-names></name></person-group>. <article-title>M-1/M-2 macrophages and the Th1/Th2 paradigm</article-title>. <source>J Immunol</source> (<year>2000</year>) <volume>164</volume>(<issue>12</issue>):<fpage>6166</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.164.12.6166</pub-id><pub-id pub-id-type="pmid">10843666</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname> <given-names>FO</given-names></name> <name><surname>Gordon</surname> <given-names>S</given-names></name></person-group>. <article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title>. <source>F1000Prime Rep</source> (<year>2014</year>) <volume>6</volume>:<fpage>13</fpage>.<pub-id pub-id-type="doi">10.12703/P6-13</pub-id><pub-id pub-id-type="pmid">24669294</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname> <given-names>A</given-names></name> <name><surname>Mantovani</surname> <given-names>A</given-names></name></person-group>. <article-title>Macrophage plasticity and polarization: in vivo veritas</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>(<issue>3</issue>):<fpage>787</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1172/JCI59643</pub-id><pub-id pub-id-type="pmid">22378047</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geissmann</surname> <given-names>F</given-names></name> <name><surname>Jung</surname> <given-names>S</given-names></name> <name><surname>Littman</surname> <given-names>DR</given-names></name></person-group>. <article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title>. <source>Immunity</source> (<year>2003</year>) <volume>19</volume>(<issue>1</issue>):<fpage>71</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/S1074-7613(03)00174-2</pub-id><pub-id pub-id-type="pmid">12871640</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auffray</surname> <given-names>C</given-names></name> <name><surname>Sieweke</surname> <given-names>MH</given-names></name> <name><surname>Geissmann</surname> <given-names>F</given-names></name></person-group>. <article-title>Blood monocytes: development, heterogeneity, and relationship with dendritic cells</article-title>. <source>Annu Rev Immunol</source> (<year>2009</year>) <volume>27</volume>:<fpage>669</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132557</pub-id><pub-id pub-id-type="pmid">19132917</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geissmann</surname> <given-names>F</given-names></name> <name><surname>Manz</surname> <given-names>MG</given-names></name> <name><surname>Jung</surname> <given-names>S</given-names></name> <name><surname>Sieweke</surname> <given-names>MH</given-names></name> <name><surname>Merad</surname> <given-names>M</given-names></name> <name><surname>Ley</surname> <given-names>K</given-names></name></person-group>. <article-title>Development of monocytes, macrophages, and dendritic cells</article-title>. <source>Science</source> (<year>2010</year>) <volume>327</volume>(<issue>5966</issue>):<fpage>656</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1126/science.1178331</pub-id><pub-id pub-id-type="pmid">20133564</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>LC</given-names></name> <name><surname>Jenkins</surname> <given-names>SJ</given-names></name> <name><surname>Allen</surname> <given-names>JE</given-names></name> <name><surname>Taylor</surname> <given-names>PR</given-names></name></person-group>. <article-title>Tissue-resident macrophages</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>(<issue>10</issue>):<fpage>986</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2705</pub-id><pub-id pub-id-type="pmid">24048120</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname> <given-names>D</given-names></name> <name><surname>Chow</surname> <given-names>A</given-names></name> <name><surname>Noizat</surname> <given-names>C</given-names></name> <name><surname>Teo</surname> <given-names>P</given-names></name> <name><surname>Beasley</surname> <given-names>MB</given-names></name> <name><surname>Leboeuf</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>38</volume>(<issue>4</issue>):<fpage>792</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.004</pub-id><pub-id pub-id-type="pmid">23601688</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname> <given-names>F</given-names></name> <name><surname>Greter</surname> <given-names>M</given-names></name> <name><surname>Leboeuf</surname> <given-names>M</given-names></name> <name><surname>Nandi</surname> <given-names>S</given-names></name> <name><surname>See</surname> <given-names>P</given-names></name> <name><surname>Gokhan</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Fate mapping analysis reveals that adult microglia derive from primitive macrophages</article-title>. <source>Science</source> (<year>2010</year>) <volume>330</volume>(<issue>6005</issue>):<fpage>841</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1126/science.1194637</pub-id><pub-id pub-id-type="pmid">20966214</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greter</surname> <given-names>M</given-names></name> <name><surname>Helft</surname> <given-names>J</given-names></name> <name><surname>Chow</surname> <given-names>A</given-names></name> <name><surname>Hashimoto</surname> <given-names>D</given-names></name> <name><surname>Mortha</surname> <given-names>A</given-names></name> <name><surname>Agudo-Cantero</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>36</volume>(<issue>6</issue>):<fpage>1031</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.027</pub-id><pub-id pub-id-type="pmid">22749353</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname> <given-names>T</given-names></name> <name><surname>Natoli</surname> <given-names>G</given-names></name></person-group>. <article-title>Transcriptional regulation of macrophage polarization: enabling diversity with identity</article-title>. <source>Nat Rev Immunol</source> (<year>2011</year>) <volume>11</volume>(<issue>11</issue>):<fpage>750</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1038/nri3088</pub-id><pub-id pub-id-type="pmid">22025054</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>PJ</given-names></name> <name><surname>Allen</surname> <given-names>JE</given-names></name> <name><surname>Biswas</surname> <given-names>SK</given-names></name> <name><surname>Fisher</surname> <given-names>EA</given-names></name> <name><surname>Gilroy</surname> <given-names>DW</given-names></name> <name><surname>Goerdt</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Macrophage activation and polarization: nomenclature and experimental guidelines</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.008</pub-id><pub-id pub-id-type="pmid">25035950</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>DO</given-names></name> <name><surname>Hamilton</surname> <given-names>TA</given-names></name></person-group>. <article-title>Molecular basis of macrophage activation: diversity and its origins</article-title>. In: <person-group person-group-type="editor"><name><surname>Lewis</surname> <given-names>CE</given-names></name> <name><surname>O&#x02019;D McGee</surname> <given-names>J</given-names></name></person-group>, editors. <source>The Natural Immune System, Volume II: The Macrophage</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford University Press</publisher-name> (<year>1992</year>). p. <fpage>75</fpage>&#x02013;<lpage>114</lpage>.</citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lichtnekert</surname> <given-names>J</given-names></name> <name><surname>Kawakami</surname> <given-names>T</given-names></name> <name><surname>Parks</surname> <given-names>WC</given-names></name> <name><surname>Duffield</surname> <given-names>JS</given-names></name></person-group>. <article-title>Changes in macrophage phenotype as the immune response evolves</article-title>. <source>Curr Opin Pharmacol</source> (<year>2013</year>) <volume>13</volume>(<issue>4</issue>):<fpage>555</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1016/j.coph.2013.05.013</pub-id><pub-id pub-id-type="pmid">23747023</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname> <given-names>A</given-names></name> <name><surname>Biswas</surname> <given-names>SK</given-names></name> <name><surname>Galdiero</surname> <given-names>MR</given-names></name> <name><surname>Sica</surname> <given-names>A</given-names></name> <name><surname>Locati</surname> <given-names>M</given-names></name></person-group>. <article-title>Macrophage plasticity and polarization in tissue repair and remodelling</article-title>. <source>J Pathol</source> (<year>2013</year>) <volume>229</volume>(<issue>2</issue>):<fpage>176</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1002/path.4133</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname> <given-names>MP</given-names></name> <name><surname>Cheng</surname> <given-names>L</given-names></name> <name><surname>Ju</surname> <given-names>C</given-names></name></person-group>. <article-title>Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury</article-title>. <source>J Leukoc Biol</source> (<year>2008</year>) <volume>84</volume>(<issue>6</issue>):<fpage>1410</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0308173</pub-id><pub-id pub-id-type="pmid">18713872</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname> <given-names>L</given-names></name> <name><surname>Henry</surname> <given-names>A</given-names></name> <name><surname>Poron</surname> <given-names>F</given-names></name> <name><surname>Baba-Amer</surname> <given-names>Y</given-names></name> <name><surname>van Rooijen</surname> <given-names>N</given-names></name> <name><surname>Plonquet</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis</article-title>. <source>J Exp Med</source> (<year>2007</year>) <volume>204</volume>(<issue>5</issue>):<fpage>1057</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20070075</pub-id><pub-id pub-id-type="pmid">17485518</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname> <given-names>FO</given-names></name> <name><surname>Helming</surname> <given-names>L</given-names></name> <name><surname>Gordon</surname> <given-names>S</given-names></name></person-group>. <article-title>Alternative activation of macrophages: an immunologic functional perspective</article-title>. <source>Annu Rev Immunol</source> (<year>2009</year>) <volume>27</volume>:<fpage>451</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132532</pub-id><pub-id pub-id-type="pmid">19105661</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzik</surname> <given-names>JM</given-names></name></person-group>. <article-title>The ancestry and cumulative evolution of immune reactions</article-title>. <source>Acta Biochim Pol</source> (<year>2010</year>) <volume>57</volume>(<issue>4</issue>):<fpage>443</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">21046016</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefater</surname> <given-names>JA</given-names> <suffix>III</suffix></name> <name><surname>Ren</surname> <given-names>S</given-names></name> <name><surname>Lang</surname> <given-names>RA</given-names></name> <name><surname>Duffield</surname> <given-names>JS</given-names></name></person-group>. <article-title>Metchnikoff&#x02019;s policemen: macrophages in development, homeostasis and regeneration</article-title>. <source>Trends Mol Med</source> (<year>2011</year>) <volume>17</volume>(<issue>12</issue>):<fpage>743</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmed.2011.07.009</pub-id><pub-id pub-id-type="pmid">21890411</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname> <given-names>A</given-names></name> <name><surname>Wilson</surname> <given-names>NS</given-names></name> <name><surname>Yang</surname> <given-names>B</given-names></name> <name><surname>Paler Martinez</surname> <given-names>A</given-names></name> <name><surname>Liu</surname> <given-names>J</given-names></name> <name><surname>Zhu</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages</article-title>. <source>Immunol Cell Biol</source> (<year>2013</year>) <volume>91</volume>(<issue>7</issue>):<fpage>451</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/icb.2013.27</pub-id><pub-id pub-id-type="pmid">23817579</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname> <given-names>A</given-names></name> <name><surname>Kokkola</surname> <given-names>R</given-names></name> <name><surname>Wefer</surname> <given-names>J</given-names></name> <name><surname>Erlandsson-Harris</surname> <given-names>H</given-names></name> <name><surname>Harris</surname> <given-names>RA</given-names></name></person-group>. <article-title>Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility</article-title>. <source>J Leukoc Biol</source> (<year>2004</year>) <volume>76</volume>(<issue>6</issue>):<fpage>1118</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0704385</pub-id><pub-id pub-id-type="pmid">15371491</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname> <given-names>JA</given-names></name> <name><surname>Achuthan</surname> <given-names>A</given-names></name></person-group>. <article-title>Colony stimulating factors and myeloid cell biology in health and disease</article-title>. <source>Trends Immunol</source> (<year>2013</year>) <volume>34</volume>(<issue>2</issue>):<fpage>81</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2012.08.006</pub-id><pub-id pub-id-type="pmid">23000011</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname> <given-names>JA</given-names></name></person-group>. <article-title>Colony-stimulating factors in inflammation and autoimmunity</article-title>. <source>Nat Rev Immunol</source> (<year>2008</year>) <volume>8</volume>(<issue>7</issue>):<fpage>533</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/nri2356</pub-id><pub-id pub-id-type="pmid">18551128</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname> <given-names>DY</given-names></name> <name><surname>Glim</surname> <given-names>JE</given-names></name> <name><surname>Stavenuiter</surname> <given-names>AW</given-names></name> <name><surname>Breur</surname> <given-names>M</given-names></name> <name><surname>Heijnen</surname> <given-names>P</given-names></name> <name><surname>Amor</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Human macrophage polarization in vitro: maturation and activation methods compared</article-title>. <source>Immunobiology</source> (<year>2014</year>) <volume>219</volume>(<issue>9</issue>):<fpage>695</fpage>&#x02013;<lpage>703</lpage>.<pub-id pub-id-type="doi">10.1016/j.imbio.2014.05.002</pub-id><pub-id pub-id-type="pmid">24916404</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Page</surname> <given-names>AV</given-names></name> <name><surname>Liles</surname> <given-names>WC</given-names></name></person-group>. <article-title>Colony-stimulating factors in the prevention and management of infectious diseases</article-title>. <source>Infect Dis Clin North Am</source> (<year>2011</year>) <volume>25</volume>(<issue>4</issue>):<fpage>803</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1016/j.idc.2011.07.007</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akagawa</surname> <given-names>KS</given-names></name></person-group>. <article-title>Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages</article-title>. <source>Int J Hematol</source> (<year>2002</year>) <volume>76</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="doi">10.1007/BF02982715</pub-id><pub-id pub-id-type="pmid">12138892</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verreck</surname> <given-names>FA</given-names></name> <name><surname>de Boer</surname> <given-names>T</given-names></name> <name><surname>Langenberg</surname> <given-names>DM</given-names></name> <name><surname>Hoeve</surname> <given-names>MA</given-names></name> <name><surname>Kramer</surname> <given-names>M</given-names></name> <name><surname>Vaisberg</surname> <given-names>E</given-names></name> <etal/></person-group> <article-title>Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2004</year>) <volume>101</volume>(<issue>13</issue>):<fpage>4560</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0400983101</pub-id><pub-id pub-id-type="pmid">15070757</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verreck</surname> <given-names>FA</given-names></name> <name><surname>de Boer</surname> <given-names>T</given-names></name> <name><surname>Langenberg</surname> <given-names>DM</given-names></name> <name><surname>van der Zanden</surname> <given-names>L</given-names></name> <name><surname>Ottenhoff</surname> <given-names>TH</given-names></name></person-group>. <article-title>Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation</article-title>. <source>J Leukoc Biol</source> (<year>2006</year>) <volume>79</volume>(<issue>2</issue>):<fpage>285</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1189/jlb.0105015</pub-id><pub-id pub-id-type="pmid">16330536</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleetwood</surname> <given-names>AJ</given-names></name> <name><surname>Lawrence</surname> <given-names>T</given-names></name> <name><surname>Hamilton</surname> <given-names>JA</given-names></name> <name><surname>Cook</surname> <given-names>AD</given-names></name></person-group>. <article-title>Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>178</volume>(<issue>8</issue>):<fpage>5245</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.178.8.5245</pub-id><pub-id pub-id-type="pmid">17404308</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inaba</surname> <given-names>K</given-names></name> <name><surname>Inaba</surname> <given-names>M</given-names></name> <name><surname>Romani</surname> <given-names>N</given-names></name> <name><surname>Aya</surname> <given-names>H</given-names></name> <name><surname>Deguchi</surname> <given-names>M</given-names></name> <name><surname>Ikehara</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor</article-title>. <source>J Exp Med</source> (<year>1992</year>) <volume>176</volume>(<issue>6</issue>):<fpage>1693</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="doi">10.1084/jem.176.6.1693</pub-id><pub-id pub-id-type="pmid">1460426</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacey</surname> <given-names>DC</given-names></name> <name><surname>Achuthan</surname> <given-names>A</given-names></name> <name><surname>Fleetwood</surname> <given-names>AJ</given-names></name> <name><surname>Dinh</surname> <given-names>H</given-names></name> <name><surname>Roiniotis</surname> <given-names>J</given-names></name> <name><surname>Scholz</surname> <given-names>GM</given-names></name> <etal/></person-group> <article-title>Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>(<issue>11</issue>):<fpage>5752</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1103426</pub-id><pub-id pub-id-type="pmid">22547697</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname> <given-names>M</given-names></name> <name><surname>Mallmann</surname> <given-names>MR</given-names></name> <name><surname>Xue</surname> <given-names>J</given-names></name> <name><surname>Staratschek-Jox</surname> <given-names>A</given-names></name> <name><surname>Vorholt</surname> <given-names>D</given-names></name> <name><surname>Krebs</surname> <given-names>W</given-names></name> <etal/></person-group> <article-title>High-resolution transcriptome of human macrophages</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>(<issue>9</issue>):<fpage>e45466</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0045466</pub-id><pub-id pub-id-type="pmid">23029029</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname> <given-names>J</given-names></name> <name><surname>Schmidt</surname> <given-names>SV</given-names></name> <name><surname>Sander</surname> <given-names>J</given-names></name> <name><surname>Draffehn</surname> <given-names>A</given-names></name> <name><surname>Krebs</surname> <given-names>W</given-names></name> <name><surname>Quester</surname> <given-names>I</given-names></name> <etal/></person-group> <article-title>Transcriptome-based network analysis reveals a spectrum model of human macrophage activation</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>40</volume>(<issue>2</issue>):<fpage>274</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2014.01.006</pub-id><pub-id pub-id-type="pmid">24530056</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname> <given-names>M</given-names></name> <name><surname>Wen</surname> <given-names>H</given-names></name> <name><surname>Corsa</surname> <given-names>CA</given-names></name> <name><surname>Liu</surname> <given-names>T</given-names></name> <name><surname>Coelho</surname> <given-names>AL</given-names></name> <name><surname>Allen</surname> <given-names>RM</given-names></name> <etal/></person-group> <article-title>Epigenetic regulation of the alternatively activated macrophage phenotype</article-title>. <source>Blood</source> (<year>2009</year>) <volume>114</volume>(<issue>15</issue>):<fpage>3244</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2009-04-217620</pub-id><pub-id pub-id-type="pmid">19567879</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mia</surname> <given-names>S</given-names></name> <name><surname>Warnecke</surname> <given-names>A</given-names></name> <name><surname>Zhang</surname> <given-names>XM</given-names></name> <name><surname>Malmstrom</surname> <given-names>V</given-names></name> <name><surname>Harris</surname> <given-names>RA</given-names></name></person-group>. <article-title>An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype</article-title>. <source>Scand J Immunol</source> (<year>2014</year>) <volume>79</volume>(<issue>5</issue>):<fpage>305</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1111/sji.12162</pub-id><pub-id pub-id-type="pmid">24521472</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>H</given-names></name> <name><surname>Zhu</surname> <given-names>J</given-names></name> <name><surname>Smith</surname> <given-names>S</given-names></name> <name><surname>Foldi</surname> <given-names>J</given-names></name> <name><surname>Zhao</surname> <given-names>B</given-names></name> <name><surname>Chung</surname> <given-names>AY</given-names></name> <etal/></person-group> <article-title>Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization</article-title>. <source>Nat Immunol</source> (<year>2012</year>) <volume>13</volume>(<issue>7</issue>):<fpage>642</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2304</pub-id><pub-id pub-id-type="pmid">22610140</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>B</given-names></name> <name><surname>Qiao</surname> <given-names>L</given-names></name> <name><surname>Lu</surname> <given-names>M</given-names></name> <name><surname>Yoo</surname> <given-names>HS</given-names></name> <name><surname>Cheung</surname> <given-names>W</given-names></name> <name><surname>Mak</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>C/EBPalpha regulates macrophage activation and systemic metabolism</article-title>. <source>Am J Physiol Endocrinol Metab</source> (<year>2014</year>) <volume>306</volume>(<issue>10</issue>):<fpage>E1144</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1152/ajpendo.00002.2014</pub-id><pub-id pub-id-type="pmid">24691027</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname> <given-names>H</given-names></name> <name><surname>Holdbrooks</surname> <given-names>AT</given-names></name> <name><surname>Liu</surname> <given-names>Y</given-names></name> <name><surname>Reynolds</surname> <given-names>SL</given-names></name> <name><surname>Yanagisawa</surname> <given-names>LL</given-names></name> <name><surname>Benveniste</surname> <given-names>EN</given-names></name></person-group>. <article-title>SOCS3 deficiency promotes M1 macrophage polarization and inflammation</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>189</volume>(<issue>7</issue>):<fpage>3439</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1201168</pub-id><pub-id pub-id-type="pmid">22925925</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Festuccia</surname> <given-names>WT</given-names></name> <name><surname>Pouliot</surname> <given-names>P</given-names></name> <name><surname>Bakan</surname> <given-names>I</given-names></name> <name><surname>Sabatini</surname> <given-names>DM</given-names></name> <name><surname>Laplante</surname> <given-names>M</given-names></name></person-group>. <article-title>Myeloid-specific rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>4</issue>):<fpage>e95432</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0095432</pub-id><pub-id pub-id-type="pmid">24740015</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname> <given-names>B</given-names></name> <name><surname>Jin</surname> <given-names>W</given-names></name> <name><surname>Xu</surname> <given-names>J</given-names></name> <name><surname>Liang</surname> <given-names>Z</given-names></name> <name><surname>Yao</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Myeloid-specific disruption of tyrosine phosphatase Shp2 promotes alternative activation of macrophages and predisposes mice to pulmonary fibrosis</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>193</volume>(<issue>6</issue>):<fpage>2801</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1303463</pub-id><pub-id pub-id-type="pmid">25127857</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olefsky</surname> <given-names>JM</given-names></name> <name><surname>Glass</surname> <given-names>CK</given-names></name></person-group>. <article-title>Macrophages, inflammation, and insulin resistance</article-title>. <source>Annu Rev Physiol</source> (<year>2010</year>) <volume>72</volume>:<fpage>219</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-physiol-021909-135846</pub-id><pub-id pub-id-type="pmid">20148674</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Odegaard</surname> <given-names>JI</given-names></name> <name><surname>Ricardo-Gonzalez</surname> <given-names>RR</given-names></name> <name><surname>Goforth</surname> <given-names>MH</given-names></name> <name><surname>Morel</surname> <given-names>CR</given-names></name> <name><surname>Subramanian</surname> <given-names>V</given-names></name> <name><surname>Mukundan</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance</article-title>. <source>Nature</source> (<year>2007</year>) <volume>447</volume>(<issue>7148</issue>):<fpage>1116</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1038/nature05894</pub-id><pub-id pub-id-type="pmid">17515919</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharda</surname> <given-names>DR</given-names></name> <name><surname>Yu</surname> <given-names>S</given-names></name> <name><surname>Ray</surname> <given-names>M</given-names></name> <name><surname>Squadrito</surname> <given-names>ML</given-names></name> <name><surname>De Palma</surname> <given-names>M</given-names></name> <name><surname>Wynn</surname> <given-names>TA</given-names></name> <etal/></person-group> <article-title>Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>187</volume>(<issue>5</issue>):<fpage>2181</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1003460</pub-id><pub-id pub-id-type="pmid">21810604</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>X</given-names></name> <name><surname>Sharma</surname> <given-names>N</given-names></name> <name><surname>Kapadia</surname> <given-names>F</given-names></name> <name><surname>Zhou</surname> <given-names>G</given-names></name> <name><surname>Lu</surname> <given-names>Y</given-names></name> <name><surname>Hong</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>Kruppel-like factor 4 regulates macrophage polarization</article-title>. <source>J Clin Invest</source> (<year>2011</year>) <volume>121</volume>(<issue>7</issue>):<fpage>2736</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1172/JCI45444</pub-id><pub-id pub-id-type="pmid">21670502</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ni Gabhann</surname> <given-names>J</given-names></name> <name><surname>Hams</surname> <given-names>E</given-names></name> <name><surname>Smith</surname> <given-names>S</given-names></name> <name><surname>Wynne</surname> <given-names>C</given-names></name> <name><surname>Byrne</surname> <given-names>JC</given-names></name> <name><surname>Brennan</surname> <given-names>K</given-names></name> <etal/></person-group> <article-title>Btk regulates macrophage polarization in response to lipopolysaccharide</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>1</issue>):<fpage>e85834</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0085834</pub-id><pub-id pub-id-type="pmid">24465735</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname> <given-names>T</given-names></name> <name><surname>Takeuchi</surname> <given-names>O</given-names></name> <name><surname>Vandenbon</surname> <given-names>A</given-names></name> <name><surname>Yasuda</surname> <given-names>K</given-names></name> <name><surname>Tanaka</surname> <given-names>Y</given-names></name> <name><surname>Kumagai</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>(<issue>10</issue>):<fpage>936</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1920</pub-id><pub-id pub-id-type="pmid">20729857</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>XM</given-names></name> <name><surname>Zong</surname> <given-names>XH</given-names></name> <name><surname>Sylvestre</surname> <given-names>V</given-names></name> <name><surname>Stanley</surname> <given-names>ER</given-names></name></person-group>. <article-title>Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1</article-title>. <source>Blood</source> (<year>2004</year>) <volume>103</volume>(<issue>3</issue>):<fpage>1114</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2003-08-2739</pub-id><pub-id pub-id-type="pmid">14525772</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greter</surname> <given-names>M</given-names></name> <name><surname>Lelios</surname> <given-names>I</given-names></name> <name><surname>Pelczar</surname> <given-names>P</given-names></name> <name><surname>Hoeffel</surname> <given-names>G</given-names></name> <name><surname>Price</surname> <given-names>J</given-names></name> <name><surname>Leboeuf</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia</article-title>. <source>Immunity</source> (<year>2012</year>) <volume>37</volume>(<issue>6</issue>):<fpage>1050</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.11.001</pub-id><pub-id pub-id-type="pmid">23177320</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foucher</surname> <given-names>ED</given-names></name> <name><surname>Blanchard</surname> <given-names>S</given-names></name> <name><surname>Preisser</surname> <given-names>L</given-names></name> <name><surname>Garo</surname> <given-names>E</given-names></name> <name><surname>Ifrah</surname> <given-names>N</given-names></name> <name><surname>Guardiola</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and IFNgamma</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>(<issue>2</issue>):<fpage>e56045</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0056045</pub-id><pub-id pub-id-type="pmid">23409120</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>Y</given-names></name> <name><surname>Liu</surname> <given-names>CH</given-names></name> <name><surname>Roberts</surname> <given-names>AI</given-names></name> <name><surname>Das</surname> <given-names>J</given-names></name> <name><surname>Xu</surname> <given-names>G</given-names></name> <name><surname>Ren</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don&#x02019;t know</article-title>. <source>Cell Res</source> (<year>2006</year>) <volume>16</volume>(<issue>2</issue>):<fpage>126</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="doi">10.1038/sj.cr.7310017</pub-id><pub-id pub-id-type="pmid">16474424</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hume</surname> <given-names>DA</given-names></name> <name><surname>MacDonald</surname> <given-names>KP</given-names></name></person-group>. <article-title>Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling</article-title>. <source>Blood</source> (<year>2012</year>) <volume>119</volume>(<issue>8</issue>):<fpage>1810</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-09-379214</pub-id><pub-id pub-id-type="pmid">22186992</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenzo</surname> <given-names>JC</given-names></name> <name><surname>Turner</surname> <given-names>AL</given-names></name> <name><surname>Cook</surname> <given-names>AD</given-names></name> <name><surname>Vlahos</surname> <given-names>R</given-names></name> <name><surname>Anderson</surname> <given-names>GP</given-names></name> <name><surname>Reynolds</surname> <given-names>EC</given-names></name> <etal/></person-group> <article-title>Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation</article-title>. <source>Immunol Cell Biol</source> (<year>2012</year>) <volume>90</volume>(<issue>4</issue>):<fpage>429</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1038/icb.2011.58</pub-id><pub-id pub-id-type="pmid">21727904</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyonteck</surname> <given-names>SM</given-names></name> <name><surname>Akkari</surname> <given-names>L</given-names></name> <name><surname>Schuhmacher</surname> <given-names>AJ</given-names></name> <name><surname>Bowman</surname> <given-names>RL</given-names></name> <name><surname>Sevenich</surname> <given-names>L</given-names></name> <name><surname>Quail</surname> <given-names>DF</given-names></name> <etal/></person-group> <article-title>CSF-1R inhibition alters macrophage polarization and blocks glioma progression</article-title>. <source>Nat Med</source> (<year>2013</year>) <volume>19</volume>(<issue>10</issue>):<fpage>1264</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1038/nm.3337</pub-id><pub-id pub-id-type="pmid">24056773</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname> <given-names>DI</given-names></name> <name><surname>Ostrand-Rosenberg</surname> <given-names>S</given-names></name> <name><surname>Bronte</surname> <given-names>V</given-names></name></person-group>. <article-title>Coordinated regulation of myeloid cells by tumours</article-title>. <source>Nat Rev Immunol</source> (<year>2012</year>) <volume>12</volume>(<issue>4</issue>):<fpage>253</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1038/nri3175</pub-id><pub-id pub-id-type="pmid">22437938</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sluijter</surname> <given-names>M</given-names></name> <name><surname>van der Sluis</surname> <given-names>TC</given-names></name> <name><surname>van der Velden</surname> <given-names>PA</given-names></name> <name><surname>Versluis</surname> <given-names>M</given-names></name> <name><surname>West</surname> <given-names>BL</given-names></name> <name><surname>van der Burg</surname> <given-names>SH</given-names></name> <etal/></person-group> <article-title>Inhibition of CSF-1R supports T-cell mediated melanoma therapy</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>(<issue>8</issue>):<fpage>e104230</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0104230</pub-id><pub-id pub-id-type="pmid">25110953</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Codarri</surname> <given-names>L</given-names></name> <name><surname>Gyulveszi</surname> <given-names>G</given-names></name> <name><surname>Tosevski</surname> <given-names>V</given-names></name> <name><surname>Hesske</surname> <given-names>L</given-names></name> <name><surname>Fontana</surname> <given-names>A</given-names></name> <name><surname>Magnenat</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation</article-title>. <source>Nat Immunol</source> (<year>2011</year>) <volume>12</volume>(<issue>6</issue>):<fpage>560</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2027</pub-id><pub-id pub-id-type="pmid">21516112</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Behi</surname> <given-names>M</given-names></name> <name><surname>Ciric</surname> <given-names>B</given-names></name> <name><surname>Dai</surname> <given-names>H</given-names></name> <name><surname>Yan</surname> <given-names>Y</given-names></name> <name><surname>Cullimore</surname> <given-names>M</given-names></name> <name><surname>Safavi</surname> <given-names>F</given-names></name> <etal/></person-group> <article-title>The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF</article-title>. <source>Nat Immunol</source> (<year>2011</year>) <volume>12</volume>(<issue>6</issue>):<fpage>568</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1038/ni.2031</pub-id><pub-id pub-id-type="pmid">21516111</pub-id></citation></ref>
<ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>IK</given-names></name> <name><surname>van Nieuwenhuijze</surname> <given-names>A</given-names></name> <name><surname>Segura</surname> <given-names>E</given-names></name> <name><surname>O&#x02019;Donnell</surname> <given-names>K</given-names></name> <name><surname>Coghill</surname> <given-names>E</given-names></name> <name><surname>Hommel</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Differentiation of inflammatory dendritic cells is mediated by NF-kappaB1-dependent GM-CSF production in CD4 T cells</article-title>. <source>J Immunol</source> (<year>2011</year>) <volume>186</volume>(<issue>9</issue>):<fpage>5468</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1002923</pub-id><pub-id pub-id-type="pmid">21421852</pub-id></citation></ref>
<ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>W</given-names></name> <name><surname>Zhao</surname> <given-names>X</given-names></name> <name><surname>Daha</surname> <given-names>MR</given-names></name> <name><surname>van Kooten</surname> <given-names>C</given-names></name></person-group>. <article-title>Reversible differentiation of pro- and anti-inflammatory macrophages</article-title>. <source>Mol Immunol</source> (<year>2012</year>) <volume>53</volume>(<issue>3</issue>):<fpage>179</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2012.07.005</pub-id></citation></ref>
</ref-list>
</back>
</article>